Angle PLC's new test method improves early detection of treatment resistance in lung cancer patients using osimertinib.

Angle PLC has released research on a new method for analyzing circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in non-small cell lung cancer patients treated with AstraZeneca's osimertinib. This dual analysis technique, using the Parsortix® system, identified more patients with resistance mutations and DNA changes than single analysis methods. This could help in early detection of treatment resistance and improve patient stratification for clinical trials.

November 11, 2024
3 Articles

Further Reading